Many treatments and studies focus on the destruction of tumor cells, but very few targets of the microenvironment in which these cells develop. This means paying attention to the blood vessels, bone marrow, growth factors and cell-cell interactions and binding.The new aging experiments found that the addition of rapamycin to mice increased their food elderly life. The results were the same in Texas, Michigan and Maine.
In mouse models, Oxi4503 killed leukemia cells than to destroy the blood vessels that fed and nourished.
The initial period of two years of testing is not designed to determine if the drug is effective, but rather to determine the maximum tolerable dose. It will include three dozen people from 18 years in which the tumor is growing despite the previous treatment. The details of the tests at the National Institutes of Health website.
Oxi4503 after treatment, however, researchers have discovered that a thin layer of vital tumor tissue remained, which was powered by newly formed vessels. The cells of these vessels have an increased expression of a growth factor, as is often found in poor areas of oxygen.
Existing therapies that destroy the blood vessels targeting a growth factor called VEGF-A, but are not effective in the long term to eradicate leukemia. In an attempt to find a strategy that has attacked various targets, the researchers tested Oxi4503, new blood vessels that disrupt the agent.
The use of treatment in mouse models, or acute myelogenous leukemia, is described online and in upcoming print edition in the journal Blood. Scientists are planning human trials of the drug UF Shands at least by the end of the year.
A new therapy in a double attack is aimed not only cells, but also the environment in which these cells live and grow, the University of Florida researchers report.
The research, funded by the National Institutes of Health and the Leukemia and Lymphoma Society, has implications for both basic science and clinical research, the results suggest that potential therapies must be protected against not only leukemia cells, but also environment with which interact.
To stop the formation of secondary blood vessels, the researchers blocked the growth factor VEGF by administering an antibody called bevacizumab after the destruction of blood vessels OXi4503 agent. The combined approach has led to regression of leukemia improved.
How to hit an enemy directly and cut off its source of food and other resources, the agent called Oxi4503, poisons leukemia cells and destroys the blood vessels that supply oxygen and nutrients.
?The results are very interesting and should be implemented clinically in a very hierarchical and timely,? said Karp, who was not affiliated with the study.
Source: http://www.exercise24.org/?p=480
patti smith lottery winners lottery winners april fools day pranks ohio state vs kansas daniel von bargen the beach
No comments:
Post a Comment